GWM Advisors LLC lifted its holdings in Eli Lilly And Co (NYSE:LLY) by 2.0% during the 2nd quarter, Holdings Channel reports. The fund owned 12,138 shares of the company’s stock after acquiring an additional 241 shares during the quarter. GWM Advisors LLC’s holdings in Eli Lilly And Co were worth $1,345,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Bessemer Group Inc. raised its position in shares of Eli Lilly And Co by 2,354.5% during the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after acquiring an additional 546,307 shares during the last quarter. Janney Capital Management LLC bought a new stake in shares of Eli Lilly And Co during the 1st quarter valued at $246,000. Thoroughbred Financial Services LLC raised its position in shares of Eli Lilly And Co by 1.4% during the 1st quarter. Thoroughbred Financial Services LLC now owns 7,612 shares of the company’s stock valued at $988,000 after acquiring an additional 105 shares during the last quarter. Smithfield Trust Co. raised its position in shares of Eli Lilly And Co by 1.6% during the 1st quarter. Smithfield Trust Co. now owns 7,277 shares of the company’s stock valued at $944,000 after acquiring an additional 114 shares during the last quarter. Finally, Cedar Capital LLC raised its position in shares of Eli Lilly And Co by 17.5% during the 2nd quarter. Cedar Capital LLC now owns 2,459 shares of the company’s stock valued at $272,000 after acquiring an additional 367 shares during the last quarter. 78.92% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Michael J. Harrington sold 16,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the transaction, the vice president now directly owns 110,300 shares in the company, valued at approximately $12,874,216. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Joshua L. Smiley acquired 426 shares of Eli Lilly And Co stock in a transaction dated Wednesday, June 5th. The shares were acquired at an average price of $118.03 per share, with a total value of $50,280.78. Following the completion of the purchase, the chief financial officer now owns 30,410 shares in the company, valued at $3,589,292.30. The disclosure for this purchase can be found here. Corporate insiders own 0.11% of the company’s stock.

Shares of NYSE LLY opened at $112.07 on Wednesday. The firm has a market cap of $106.70 billion, a PE ratio of 20.19, a PEG ratio of 1.95 and a beta of 0.19. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 4.98. Eli Lilly And Co has a 1-year low of $103.65 and a 1-year high of $132.13. The company has a fifty day moving average price of $110.61 and a 200 day moving average price of $117.89.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The firm had revenue of $5.64 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the business earned $1.48 EPS. The company’s revenue for the quarter was up .9% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly And Co will post 5.72 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $0.645 per share. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.30%. Eli Lilly And Co’s dividend payout ratio is 46.49%.

Several brokerages have commented on LLY. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $143.00 target price on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. TheStreet cut shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a research report on Thursday, May 9th. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a research report on Tuesday, April 23rd. Finally, BMO Capital Markets upped their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Eli Lilly And Co presently has an average rating of “Buy” and an average price target of $123.49.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Total Return

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.